Cookie Policy

Silence Therapeutics website uses cookies. By continuing to browse you are agreeing to our use of cookies.

Privacy and cookie notice
Menu
SilenceLogo_255x56.svg logo-footer.png
Contact
Share price : 550.05 p 10.05p
  • About us

    Channelling gene silencing to cure disease.

    Management Team

    Our management team is highly experienced in a variety of relevant sectors, from molecular biology and genetics to pharmaceutical development, BD deals and corporate finance.

    Strategy

    Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value.

    Corporate Responsibility

    Silence Therapeutics strives to conduct its business in an ethical, responsible and transparent manner.

    Board of Directors

    Our Board of Directors is formed by six accomplished members, one Executive and five Non-Executive Directors.

    Technology Advisory Board

    As the RNA field evolves at an ever-faster rate, our Technology Advisory Board helps us to assess its competitive position in technology and offers guidance in developing it in the most effective way.

    Careers

    We offer a vibrant culture and environment where innovation and creativity is encouraged.

    Downloads

    sept 2019 corp pres pic.JPG
    • Silence Therapeutics Corporate Presentation Nov 2019.pdf

    Download the Corporate Presentation here

  • Pipeline
  • Our technology

    Our technology is a highly specific and modular platform that enables us to inhibit or ‘silence’ the expression of disease-causing genes, allowing cells to revert to their healthy state.

    Partnerships & Collaborations

    We are committed to creating collaborations that maximise value for each of the partners.

    Intellectual Property

    We have established, maintained and actively pursue intellectual property protection for our technology.

    RNA Interference

    Discover how our siRNA based therapies work

    Delivery Platform

    Effective siRNA delivery to the right cells is a challenge given the complexity of the human body. Discover how we address this.

    Downloads

    sept 2019 corp pres pic.JPG
    • Silence Therapeutics Corporate Presentation Nov 2019.pdf

    Download the Corporate Presentation here

  • Investors

    Find out more about our investment case, share price, corporate governance and related information. Download our latest reports and announcements.

    Results, reports & presentations

    View and download our Results, reports & presentations.

    Shareholder information & key advisers

    A summary of relevant information for our shareholders, investor FAQs and key adviser details.

    Corporate Governance

    Read more about our exisiting corporate governance arrangements.

    AIM Rule 26 checklist

    AIM Rule 26 checklist.

    Regulatory Announcements

    All regulatory news.

    Share price information

    Share price information and major shareholders.

    Email Alerts

    Login or Register to our email alerts.

    Downloads

    sept 2019 corp pres pic.JPG
    • Silence Therapeutics Corporate Presentation Nov 2019.pdf

    Download the Corporate Presentation here

  • News & media

    View our latest news, publications and videos here.

    Latest News

    View our Latest News here.

    Events

    Upcoming and past events.

    Press Coverage

    View our Press Coverage here.

    Publications

    View our Publications here.

    Videos

    View our Videos here.

    Downloads

    sept 2019 corp pres pic.JPG
    • Silence Therapeutics Corporate Presentation Nov 2019.pdf

    Download the Corporate Presentation here

  • Contact
Share price: 550.05p 10.05p
Videos toggler
  • Latest News
  • Events
  • Press Coverage
  • Publications
  • Videos
  • Home >
  • News & media >
  • Videos

Videos

David Solomon - Proactive Interview 281119.PNG
November 28th, 2019

Silence Therapeutics CEO talks recent RNAi deals and updates on critical SLN124 trial

  • Latest News
  • Events
  • Press Coverage
  • Publications
  • Videos
Logo footer
  • About us
  • Pipeline
  • Our technology
  • Investors
  • News & media
Email alerts

Corporate Headquarters

UK

72 Hammersmith Road,
London,
W14 8TH
Tel: +44 (0)20 3457 6900

Germany

Robert-Rossle-Str. 10
D-13125 Berlin
Germany
Tel: +49 30 9489 2800
Website by Luminous
  • Privacy and cookie notice
  • Terms of use

© Silence Therapeutics 2018. 'Silence Therapeutics', 'Silence', the Silence logo, and AtuRNAi are all trademarks of Silence Therapeutics